Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
about
The A's, G's, C's, and T's of health disparitiesClinical implications of chronic heart failure phenotypes defined by cluster analysis.The spectre of race in American medicine.Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.Ethnicity and variation in prognosis for patients newly hospitalised for heart failure: a matched historical cohort study.Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure.Cardiovascular health disparities: a systematic review of health care interventions.Epidemiologic analysis of racial/ethnic disparities: some fundamental issues and a cautionary example.Ethnic differences in cardiovascular drug response: potential contribution of pharmacogeneticsEndothelial dysfunction as a potential contributor in diabetic nephropathy.Heart failure in hypertension: prevention and treatment.Hypertension as a risk factor for heart failure.Current treatment of heart failure with reduction of left ventricular ejection fraction.Association of race, heart failure and chronic kidney disease.Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study.Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database.Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure.Treatment of high-risk African American patients: left ventricular dysfunction, heart failure, renal disease, and postmyocardial infarction.
P2860
Q28752470-5D0FB7DD-0405-4FF0-AEFC-DFB4774ED920Q30604593-EE43B0B0-25B7-4ED2-B52E-CC73BD2A4F4AQ34039428-063C1B0E-5699-4C68-AD58-90D0B43FCA01Q35088348-606436B8-A8A3-4F81-841B-0BEB8A65C82EQ35585101-37E6669B-E19D-44EF-9451-7888883A0BDDQ35820248-AA013192-E086-4943-93C5-DB10F365E742Q36632231-A3C42EDB-663A-45DE-BA1A-F041B1F5FC99Q37076637-576DB748-9658-4E8A-9C0A-0AFF2D1C419DQ37276490-2EF09DCD-D9B7-45D7-9925-EA21889674BBQ37806614-9C4389BB-3415-4314-9585-83C6D5D1AB83Q38022713-862C57F9-B8DE-4D51-A692-1F5468B24F6CQ38208967-68DEBBC9-4288-42D5-9956-D27210B90824Q38965647-221347EF-9F82-4F40-BDF0-36E3487FD0CFQ40311503-DE5B1E39-4BD6-4CE9-86E6-5F479CE7D411Q42644663-6D43D2B7-2B68-4C9C-BDE2-CF7303302E72Q45325795-7F22787C-6C9A-417C-B6C7-38F6AC9D1655Q46144529-7B6BBE88-4604-4BC5-84C7-C5C21F40AB63Q46635911-C36360D0-8D05-4E92-89B5-AC2D51FD606C
P2860
Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy of angiotensin-conver ...... e in black and white patients.
@ast
Efficacy of angiotensin-conver ...... e in black and white patients.
@en
type
label
Efficacy of angiotensin-conver ...... e in black and white patients.
@ast
Efficacy of angiotensin-conver ...... e in black and white patients.
@en
prefLabel
Efficacy of angiotensin-conver ...... e in black and white patients.
@ast
Efficacy of angiotensin-conver ...... e in black and white patients.
@en
P2093
P1476
Efficacy of angiotensin-conver ...... e in black and white patients.
@en
P2093
Daniel L Dries
Mark H Drazner
Mark H Strong
Richard S Cooper
P304
P356
10.1016/S0735-1097(02)01943-5
P407
P577
2002-07-01T00:00:00Z